NCT04883528 - Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

June 13, 2023

Study Completion Date

June 13, 2023

Conditions

Covid19

Interventions

DRUG

Sacubitril / Valsartan Oral Tablet [Entresto]

sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.

DRUG

Placebo

sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.

Trial Locations (1)

Duke University Medical Center, Durham